GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Peptide
Comment: This compound is a peptidomimetic, covalent and reversible inhibitor of the main protease (Mpro) of coronaviruses SARS-CoV, SARS-CoV-2 and MERS-CoV [1-2]. It does not inhibit human cathepsin L (hCatL).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||
| References |
|
1. Caffrey CR, O'donoghue AJ, Serafim MSM. (2024)
Methods for inhibition of viral infection. Patent number: WO2024263680A1. Assignee: University of California Berkeley, University of California San Diego UCSD. Priority date: 20/06/2024. Publication date: 26/12/2024. |
|
2. Sá Magalhães Serafim M, Kronenberger T, Francisco KR, de Sousa Reis EV, Gonçalves de Oliveira E, Marcelino E Oliveira FK, Serraglio Fortes I, Maciel Fernandes TH, Barbosa da Silva E, Fajtova P et al.. (2025)
Discovery of benzyl carbamate inhibitors of coronavirus Mpro enzymes from a legacy collection of cysteine protease inhibitors. J Enzyme Inhib Med Chem, 40 (1): 2585619. [PMID:41246830] |